Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI115
- Development stage
- Phase 1
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IBI115 is a recombinant humanized monoclonal antibody targeting Delta-like ligand 3 (DLL3), currently under development by Innovent Biologics. DLL3 is an inhibitory Notch ligand that is highly and specifically expressed on the surface of small cell lung cancer (SCLC) and other neuroendocrine tumors, while remaining largely absent in healthy tissues. By binding specifically to DLL3, IBI115 is designed to provide a targeted therapeutic approach, potentially mediating anti-tumor activity through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) or by interfering with Notch signaling pathways. It is currently being evaluated in Phase 1 clinical trials as both a monotherapy and in combination with other agents, such as sintilimab, for the treatment of advanced SCLC.
- Other names
- anti-DLL3 monoclonal antibodyanti-DLL-3 monoclonal antibodyanti-DLL 3 monoclonal antibody
02
Targets
DLL3 (Delta-like ligand 3)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on IBI115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI115.